 GERMANTOWN, Md., March 23, 2021 PRNewswire -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the first patient has been dosed in the Phase I study of PRGN-2012, a first-in-class, investigational off-the-shelf OTS AdenoVerseTM immunotherapy in adult patients with recurrent respiratory papillomatosis RRP clinical trial identifier: NCT04724980. 